Selventa Expands From Informatics Services to MDx Development With Test to Guide RA Therapy | GenomeWeb

NEW YORK (GenomeWeb) – Selventa, a company which has largely operated as an informatics/omics service provider to date, is now branching out with a molecular test for rheumatoid arthritis called ClarifyRA, which it intends to develop into a broad profiling tool to help physicians predict patients' responses to a variety of RA drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.